Cytokinetics, Incorporated
CYTK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,267,492 | $8,058,789 | $4,115,782 | $3,504,464 |
| - Cash | $94,857 | $113,024 | $65,582 | $112,666 |
| + Debt | $788,677 | $755,771 | $749,342 | $269,930 |
| Enterprise Value | $5,961,312 | $8,701,536 | $4,799,542 | $3,661,728 |
| Revenue | $18,474 | $7,530 | $94,588 | $70,428 |
| % Growth | 145.3% | -92% | 34.3% | – |
| Gross Profit | -$320,934 | -$322,593 | -$146,225 | -$89,510 |
| % Margin | -1,737.2% | -4,284.1% | -154.6% | -127.1% |
| EBITDA | -$493,483 | -$456,684 | -$329,400 | -$176,345 |
| % Margin | -2,671.2% | -6,064.9% | -348.2% | -250.4% |
| Net Income | -$589,526 | -$526,244 | -$388,955 | -$215,314 |
| % Margin | -3,191.1% | -6,988.6% | -411.2% | -305.7% |
| EPS Diluted | -5.26 | -5.45 | -4.33 | -2.8 |
| % Growth | 3.5% | -25.9% | -54.6% | – |
| Operating Cash Flow | -$395,890 | -$414,333 | -$299,516 | -$142,522 |
| Capital Expenditures | -$3,906 | -$1,416 | -$11,335 | -$48,872 |
| Free Cash Flow | -$399,796 | -$415,749 | -$310,851 | -$191,394 |